Allergy Therapeutics (LON:AGY) Stock Price Down 11.3% – Here’s What Happened

Shares of Allergy Therapeutics plc (LON:AGY) dropped 11.3% during trading on Wednesday . The company traded as low as GBX 6.18 and last traded at GBX 6.30. 225,345 shares changed hands during trading, a decline of 17% from the average session volume of 271,766 shares. The stock had previously closed at GBX 7.10.

Allergy Therapeutics Stock Performance

The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The stock has a 50 day moving average price of GBX 9.07 and a two-hundred day moving average price of GBX 10.34. The company has a market cap of £398.95 million, a P/E ratio of -6.49, a price-to-earnings-growth ratio of -30.70 and a beta of 0.85.

Allergy Therapeutics (LON:AGY) last posted its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%.The firm had revenue of GBX 3,628 million for the quarter. On average, research analysts predict that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.